Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 53Lymphoid 25Myeloid 19Breast 18Thoracic 12Gastrointestinal 10Genitourinary 9Sarcoma 6Dermatologic 6CNS 6Head & Neck 4Gynecologic 3Plasma cell 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 293Lenalidomide 162Bortezomib 160Cyclophosphamide 121Calcium Dobesilate 118Melphalan 116fludarabine phosphate 75carfilzomib 62pomalidomide 57Whole-Body Irradiation 57Mycophenolic Acid 56Granulocyte Colony-Stimulating Factor 55Peripheral Blood Stem Cell Transplantation 54Filgrastim 54fludarabine 50daratumumab 50Tacrolimus 45Busulfan 45ixazomib 42Thalidomide 37Cyclosporine 32Stem Cell Transplantation 29dexamethasone acetate 28Antilymphocyte Serum 26dexamethasone 21-phosphate 23plerixafor 21elotuzumab 20auricularum 20belantamab mafodotin 19Prednisone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Dasatinib × Plasma cell × Clear all
NCT00560352 2017-03-13

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Bristol-Myers Squibb

Phase 1 Terminated
16 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT00560391 2016-08-04

Dasatinib in Combination With Revlimid (and Dexamethasone)

Bristol-Myers Squibb

Phase 1 Completed
35 enrolled 18 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡